The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) has moved past its initial implementation and adaptation phase to enter a state of full operational maturity.
GO STRAIGHT TO THE TOPIC THAT INTERESTS YOU MOST
00:00 – Technical Analysis: What is MoCRA?
00:32 –Facility Registration (Form 5066)
01:20 –Product Listing (Form 5067)
01:49 – FEI (Facility Establishment Identifier) Validation THE CRITICAL POINT..
02:17 – Consequences: Detentions and FDA Enforcement
02:43 – Responsible Person: Who assumes the legal risk?
03:06 – Mandatory recall authority
03:33 – Scientific Safety Substantiation (PSS/PSR)
03:58 – Adequate evidence required by the FDA
04:27 – The legal danger of lacking scientific support
05:05 – Serious adverse events and 15-day reporting
05:36 – Preparation for audits and records (6 years)
06:07 – Exemptions for small businesses ($1M limits)
06:31 – Exclusions by risk (ocular, internal, injectable)
06:56 – The 4 strategic mistakes that cost the most money
07:47 – Invitation and Exclusive Resources
The U.S. Food and Drug Administration (FDA) has moved past the “awareness” phase and adopted an active oversight and enforcement posture.
For formulation chemists, regulatory affairs teams, contract manufacturers, and brand owners, this shift dismantles decades of voluntary self‑regulation and imposes a mandatory federal framework, where formulation is now an integral part of legal compliance.
Supply chain traceability and biennial renewal
2026 marks the first major mandatory biennial renewal cycle for facilities registered in early 2024. The FDA has updated its Cosmetics Direct portal, incorporating real‑time indicators for “Registration Status” and “Renewal Date,” enabling strict tracking of deadlines.
This administrative requirement has transformed the dynamic between brands (“Responsible Persons”) and their manufacturers (contract manufacturers). In 2026, the FDA Establishment Identifier (FEI) has evolved from a simple technical data point into a Key Performance Indicator (KPI) within supply‑chain quality agreements.
It is important to understand that the systems are interconnected: a brand cannot legally list its products if its contract manufacturer has not maintained an active facility registration.
The Safety Substantiation Dossier
The most profound change under MoCRA’s active enforcement is that safety substantiation has shifted from a post‑development checklist to a foundational requirement from the moment a formula is conceived. The FDA requires every marketed cosmetic product to be supported by adequate scientific evidence.
To meet this high evidentiary standard, the industry has standardized the creation of Product Safety Substantiation Dossiers (PSSD). Brands must be prepared to defend these documents during FDA inspections. A complete and “inspectable” PSSD must include:
Exact qualitative and quantitative (Q&Q) formula breakdown. Toxicological Risk Assessment (TRA) performed by a qualified safety assessor. Preservative Efficacy Testing (PET) and stability/packaging compatibility data. Certificates of Analysis (COA) documenting absence of heavy metals, impurities, and residual solvents.
This level of rigor marks the end of “common‑knowledge safety.” Smaller manufacturers unable to provide exhaustive toxicological data for their raw materials are being displaced by brands that cannot risk marketing unsupported formulas.
Post‑market monitoring and record‑access authority
With new draft guidance released in early 2026, the FDA has clearly outlined how it will exercise its inspection powers. Section 605 grants the agency authority to access a company’s Adverse Event Records. Serious adverse events must be reported within 15 business days, requiring brands to maintain rigorous SOPs for receiving, categorizing, and reporting complaints.
Even more critical is Section 610. If the FDA has a “reasonable belief” that a product poses a threat of Serious Adverse Health Consequences or Death (SAHCOD), it may immediately access manufacturing records, raw‑material receipts, analytical test results, and customer distribution lists.
Consequences for non‑compliance are severe: refusing access to records is considered a prohibited act, potentially resulting in civil actions, federal criminal proceedings, and import refusals at the U.S. border. If a brand refuses to recall a dangerous product, the FDA now has Mandatory Recall Authority to order its removal from the market.
Warning Letters and the focus on “Hybrid” products
As evidence of this enforcement phase, the FDA has drastically increased the issuance of Warning Letters throughout 2026. Regulatory scrutiny is heavily focused on the “cosmeceutical” space—products that claim to alter physiological functions but are marketed as cosmetics.
Manufacturers of hybrid products (those crossing the line between cosmetics and OTC drugs, such as sunscreens or acne treatments) are undergoing strict audits to verify compliance with pharmaceutical‑grade GMPs, including shared‑equipment controls, cleaning validation, and active‑ingredient stability studies.
Compliance as a competitive advantage
For B2B companies and cosmetic brands, the message in 2026 is clear: MoCRA is no longer a one‑time administrative hurdle but a dynamic framework for continuous quality management.
The most successful brands will automate adverse‑event monitoring, demand full transparency from raw‑material suppliers, and structure formulations from day zero with federal audits in mind. Centralizing technical documentation and maintaining partnerships with properly registered manufacturers (with active FEI and verified U.S. Agent) is not only a legal necessity but has become the strongest competitive advantage in a market that now demands explicit scientific proof of safety.
Which products must be listed and which are exempt?
Mandatory: All cosmetic products marketed in the United States must be listed with the FDA.
Exemptions: “Small businesses” (those with average annual U.S. cosmetic sales under $1 million over the past three years) are exempt from product listing.
Exceptions to the exemption: The exemption is void if the product contacts the eye’s mucous membrane, is injectable, is intended for internal use, or alters appearance for more than 24 hours without customary removal. Products subject to drug or medical‑device requirements are also excluded from MoCRA.
What information must be included in the registration and listing?
Facility Registration: Must include the facility name, physical address, email, phone number, FDA FEI number, all brand names manufactured there, product categories, Responsible Person information, and U.S. Agent designation for foreign facilities.
Product Listing: Must include product name, brand, cosmetic category (e.g., shampoo, cream), full ingredient list (including flavors and fragrances), and the FEI number of the manufacturing facility or facilities.
What risks does a company face if it fails to register its facility or list its products?
Legal actions: Failure to register or list is a “prohibited act.” The FDA may issue Warning Letters, initiate civil actions, or pursue federal criminal charges.
Suspension and adulteration: If the FDA determines a product may cause serious harm, it may suspend the facility’s registration. Once suspended, distributing or selling any product from that facility in the U.S. becomes illegal. Products from unregistered facilities may be deemed adulterated or misbranded.
Border blockage: For foreign companies, non‑compliance may result in import detentions (DWPE), blocking entry into the U.S.
How does this affect brands that manufacture through third parties (contract manufacturers)?
It directly affects operational viability and supply‑chain continuity, as facility registration and product listing are interconnected systems.
Logistical risk: If a brand works with a non‑compliant intermediary or factory, goods will not clear customs. FEI verification has become indispensable before signing supplier agreements.
The listing burden falls on the brand: The brand (the name on the label) is the Responsible Person and must perform the product listing.
Interdependent compliance: A brand cannot legally list its product if its contract manufacturer has not registered the facility and obtained an active FEI.
Factory transparency: Contract manufacturers must register their facility (and appoint a U.S. Agent if foreign) and must provide their FEI to the brand for product listing.
Don’t settle for reading the news.
Access the intelligence that allows you to create it.
Join the Private Circle and become part of B2B Market Intelligence.
